Company intelligence / Profile preview

EOM Pharmaceutical Holdings, Inc.

Montvale, New Jersey, United Stateseompharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company has two main pipeline assets: EOM613, a peptide-nucleic acid solution with dual-acting immunomodulatory effects currently in clinical trials for COVID-19 and planned for cancer cachexia and rheumatoid arthritis; and EOM147, a reformulated aminosterol for retinal diseases administered as eye drops rather than intraocular injections.

Therapeutic areas: OncologyOphthalmologyImmunologyInfectious Diseases
Modalities: Peptide-nucleic acid solutionsAminosterols
Industry: Biotech

Drug pipeline

9 assets

EOM613

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on EOM Pharmaceutical Holdings, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EOM Pharmaceutical Holdings, Inc..

Explore the full profile